Wall Street brokerages expect Charles River Laboratories International, Inc. (NYSE:CRL) to post sales of $459.17 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Charles River Laboratories International’s earnings, with the highest sales estimate coming in at $471.00 million and the lowest estimate coming in at $454.50 million. Charles River Laboratories International reported sales of $425.72 million during the same quarter last year, which indicates a positive year-over-year growth rate of 7.9%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Charles River Laboratories International will report full-year sales of $459.17 million for the current year, with estimates ranging from $1.83 billion to $1.87 billion. For the next year, analysts anticipate that the firm will post sales of $1.98 billion per share, with estimates ranging from $1.96 billion to $2.01 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million for the quarter, compared to the consensus estimate of $458.25 million. During the same period in the previous year, the company earned $1.20 earnings per share. The firm’s revenue for the quarter was up 8.1% on a year-over-year basis.

Several equities analysts have weighed in on the company. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price objective on the stock in a research note on Thursday, August 10th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Jefferies Group LLC restated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, June 14th. Barclays PLC reaffirmed a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Finally, Royal Bank Of Canada began coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price for the company. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories International currently has a consensus rating of “Buy” and a consensus target price of $99.59.

Charles River Laboratories International (NYSE:CRL) opened at 109.58 on Thursday. The firm has a 50 day moving average of $106.15 and a 200 day moving average of $97.03. The firm has a market capitalization of $5.22 billion, a P/E ratio of 28.87 and a beta of 0.96. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $109.74.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Charles River Laboratories International, Inc. (CRL) Will Announce Quarterly Sales of $459.17 Million” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/05/brokerages-expect-charles-river-laboratories-international-inc-crl-will-announce-quarterly-sales-of-459-17-million-2.html.

In related news, Chairman James C. Foster sold 9,516 shares of Charles River Laboratories International stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $98.92, for a total value of $941,322.72. Following the completion of the sale, the chairman now owns 361,171 shares of the company’s stock, valued at approximately $35,727,035.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David Ross Smith sold 2,552 shares of Charles River Laboratories International stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now directly owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The disclosure for this sale can be found here. In the last three months, insiders sold 25,880 shares of company stock valued at $2,541,668. 2.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in CRL. UBS Asset Management Americas Inc. increased its holdings in Charles River Laboratories International by 0.3% in the 1st quarter. UBS Asset Management Americas Inc. now owns 89,008 shares of the medical research company’s stock worth $8,006,000 after acquiring an additional 228 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Charles River Laboratories International by 3.1% in the 1st quarter. Ameriprise Financial Inc. now owns 170,698 shares of the medical research company’s stock worth $15,354,000 after acquiring an additional 5,088 shares during the last quarter. Schroder Investment Management Group increased its holdings in Charles River Laboratories International by 28.5% in the 1st quarter. Schroder Investment Management Group now owns 17,128 shares of the medical research company’s stock worth $1,535,000 after acquiring an additional 3,804 shares during the last quarter. Arizona State Retirement System increased its holdings in Charles River Laboratories International by 2.1% in the 1st quarter. Arizona State Retirement System now owns 19,700 shares of the medical research company’s stock worth $1,772,000 after acquiring an additional 406 shares during the last quarter. Finally, OppenheimerFunds Inc. increased its holdings in Charles River Laboratories International by 9.1% in the 1st quarter. OppenheimerFunds Inc. now owns 4,713 shares of the medical research company’s stock worth $424,000 after acquiring an additional 394 shares during the last quarter. 95.37% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.